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INTRODUCTION 
 
OVERVIEW: Tight glucose control (TGC) reduced intensive care unit (ICU) patient 
mortality up to 45% using a target of 6.1 mmol/L.  TGC also reduce organ failure 
rate, severity and cost. 
“Virtual trials” are performed using a clinically validated model of the glucose-
insulin system. Insulin sensitivity, SI, is used as the critical marker of a patient’s 
metabolic state and is assumed independent of the model inputs.  
Virtual trials can be used to simulate a TGC protocol using a SI profile identified 
from clinical data and different insulin and nutrition inputs.  Virtual patient trials 
have been used in design of TGC protocols . The clinical results of SPRINT showed 
very close agreement to expected results from simulation.  
The performance of virtual trials on separate cohorts, independent of the ICU 
used to generate the virtual patients, has not yet been performed.  
 
GOALS: This study provides a source of independent, matched patient data for 
two groups treated with different TGC protocols. Patients in the Glucontrol study 
were randomised into two, matched cohorts with different glycemic protocols 
and targets. Only data from one Glucontrol centre (University Hospital of Liege, 
Belgium) was used.  
Virtual trial simulations are used to assess model errors and validate the overall 
virtual trials approach. 
VIRTUAL TRIALS METHOD 
 
 
 
 
 
 
 
 
 
 
 
SELF & CROSS VALIDATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS & DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
 
 
 
 
 Self Validation indicates a clinically insignificant error in these virtual patient methods due to model and/or clinical compliance. 
 
 Cross Validation clearly shows the virtual patients enabled by the identified patient-specific SI(t) profiles are independent of the 
clinical inputs used to generate these profiles. 
 
 These outcomes validate the ability  of the virtual patients and in silico virtual trial methods presented to accurately simulate, in 
advance, the clinical results of an independent TGC protocol, directly enabling rapid design and optimisation of safe and effective 
TGC protocols with high confidence of clinical success. 
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CDFs of Blood Glucose levels for clinical Glucontrol data  
and virtual trials on a (whole cohort basis) 
 Clear separation in clinical BG results between 
Glucontrol A  and Glucontrol B indicates 
difference in protocol behaviour. 
 
 Self-validation and cross-validation results 
closely match  clinical results for both Groups 
A and B. 
 
 Cross validation result lies between the clinical 
data and self validation result indicating it is 
within the model and/or compliance error 
compared to the clinical data. 
 
 Overall, simulation results reproduce clinical 
results using any  collection of matched virtual 
patients. 
 
Wider error below 8 mmol/L is due to the fact 
that the Glucontrol B protocol requires zero 
exogenous insulin below its target.  
 
 Gap between the self validation and clinical 
data indicates the possibility of compliance 
error whereas the difference between self 
validation may be model error, but may also 
suggest that lower intensity Group B protocol 
may not have been followed as strictly.  
 
Group A 
Virtual patients 
Glucontrol A 
Control Protocol 
Simulation Code 
Group B 
Virtual patients 
Glucontrol B 
Control Protocol 
Simulation Code 
         
        
 
         
         
          
           
Group A  
Clinical Data 
Self Validation 
Cross 
Validation 
Cross 
Validation 
Group A  
Clinical Data 
Group B  
Clinical Data 
Group B  
Clinical Data 
)(
)(
1
max
tV
CNSEGPtP
Q
Q
GG
IG GSGpG
−+
+
+
−−=
α

kIkQQ +−=
B
exI
I
ex
I
Ie
V
tu
I
nII tUk )()(
1
−++
+
−=
α

SELF VALIDATION: 
• Assess the ability of in-silico 
virtual trials to reproduce the 
clinical data.  
• Differences of simulation 
results to clinical results are 
due to model errors and/or 
lack of perfect compliance. 
 
CROSS VALIDATION: 
• Test the assumption that the 
SI profiles accurately capture 
patient dynamics, 
independent of the insulin 
and nutrition inputs used to 
create them.  
• The patients in simulation will 
receive very different 
amounts of insulin compared 
to what was given clinically. 
• Both cohorts are matched 
clinically, differences can be 
ascribed to the independence 
assumption behind this virtual 
trials method.  
 
Glucose-Insulin System Model 
Cohort A B P value 
Baseline Variables 
Number 142 69   
Percent male (%) 64.8 56.5 0.25 
Age 71 [61-80] 69 [53-77] 0.035 
Weight (kg) 72 [62-85] 75 [68-81] 0.38 
BMI 
25.4  
[22.6-29.3] 
26.0  
[23.2-29.3] 0.46 
APACHE II 17 [14-22] 17 [14-21] 0.76 
Initial BG 
6.6  
[5.56-8.56] 
6.6  
[5.65-9.36] 0.58 
Glucose Control 
Total hours 16, 831 12, 946   
BG measures 4, 571 2, 820   
BG (mmol/L) 
6.3  
[5.3-7.6] 
8.2  
[6.9-9.4]   
Insulin (U/hr) 
1.5  
[0.5-3.0] 
0.7  
[0.0-1.7]   
All glucose admin 
(mmol/min) 
0.30  
[0.00-0.90] 
0.60  
[0.10-1.00]   
211 patients were treated using the Glucontrol protocol at CHU de 
Liege, Belgium, between March 2004 and April 2005. 
 Patients were randomly divided into two groups: 
•  Group A – Glucontrol A protocol. 
•  Group B – Glucontrol B protocol. 
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